OVERVIEW
Zenflex™ Pro Peripheral Drug-eluting Stent System
ZENFLEX® Pro Peripheral Drug-eluting Stent System, the 3rd peripheral drug-eluting stent in the world, is designed especially for complex lesions and restenotic symptomatic lesions.
PRODUCT FEATURES
Zenflex™ Pro Peripheral Drug-eluting Stent System
Based on ZENFLEX Peripheral stent platform
UNIQUE STENT DESIGN
Open helical structure
Segmented MicroMesh design
Offset Peak-Valley design
Results in superior flexibility and great radial force of the stent
Promises immediate wall apposition and precise stent placement
Polymer free Coating
The special ZENFLEX® Pro coating technology is a ultrasound spray crystalline paclitaxel.
Uses a special auxiliary gas to recrystallize the drug coating and obtain a stable uniform drug coating layer bonded on the stent surface.
Free from any polymer, adhesive, or excipient, while eliminating the potential risks that polymers may cause.
Provides the effective Paclitaxel tissue concentration within 90 days, and the stent converts into bare stent with complete drug delivery after 180 days
INDICATIONS
The ZENFLEX Pro™ Peripheral Drug-Eluting Stent System is indicated for improving luminal diameter in the treatment of de novo or restenotic symptomatic lesion(s) in native vascular disease of the above-the-knee femoropopliteal arteries with reference vessel diameter from 4.0 mm to 6.5 mm.
As a fully integrated medical device company, Ton-bridge has strong R&D and manufacturing capabilities, multiple specialized technology platforms, and proven commercialization capabilities.
You must be logged in to post a comment.